Vietnam
Industry
BMI View: Over the short and medium term, we do not expect Vietnam and Cambodia to interest clinical trials organisations (CROs) significantly, unless improvements are made to their...
2011-10-10Industry
BMI View: The local production of vaccines in Vietnam will allow for their increased consumption due to improving affordability. However, over the medium term, BMI believes that the...
2011-07-11Industry
BMI View: Vietnam's VND32,886bn (US$1.71bn) pharmaceutical market represents a moderate risk, high-return proposition for drugmakers. Demand for medicines is supported by a booming...
2011-03-28Industry
BMI View: Vietnam's US$1.7bn pharmaceutical market has a classic risk/reward profile. Combined sales of prescription drugs and over-the-counter (OTC) medicines are forecast to increase...
2011-01-25Industry
BMI Core View: Drugmakers based in emerging markets will increasingly produce hard-to-manufacture pharmaceuticals. Firms in developing countries enjoy low operating costs, but have...
2011-01-06Industry
BMI Core View: Drugmakers will increasingly use differential pricing in emerging markets. Pharmaceutical companies generally price their patented medicines at the maximum the market...
2010-11-30Economy
Developed state underperformance remains a recurring theme within our Industry analysis. We remain concerned about US labour market weakness and its impact, particularly on consumer...
2010-09-28Industry
It is BMI's view that corruption is a significant problem in Vietnam. The payment of bribes increases transaction costs, diverting resources away from more productive uses. The ultimate...
2010-04-01
